Tolerability of Grazax-R in Children

Phase 1

Completed

• Conditions: Allergy

• Registration Number: NCT00298701
• Lead Sponsor: ALK-Abelló A/S

Brief Summary

This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2006-03-01
• Study First Submitted QC: 2006-03-01
• Study First Posted: 2006-03-03
• Study Completion: 2006-04
• Status Verified: 2006-05
• Last Update Submitted: 2006-05-03
• Last Update Posted: 2006-05-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Grass pollen induced rhinoconjunctivitis
• Boys and girls, 5-12 years of age
• Positive skin prick test to grass pollen

Exclusion Criteria

• Previous treatment with immunotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Assessment of safety by recording of adverse events

Trial Locations

Locations (1)

Tangstedter Landstrasse 77; 🇩🇪 Hamburg, Germany